Increasing launches and approvals of new resveratrol products in the market is expected to drive the global resveratrol market growth during the forecast period. For instance, in, 2016, VitaMonk, a natural products manufacturer company, expanded its portfolio with the launch of resveratrol and pterostilbene products. Resveratrol and pterostilbene are powerful antioxidants and work together to help the body to naturally boost production of adenosine triphosphate (ATP).
Request for a sample of this research report @ https://www.coherentmarketinsights.com/insight/request-sample/2267
Furthermore, rising prevalence of ageing population, cardiovascular diseases, cancer, diabetes, neurological diseases and others are expected to rise demand for resveratrol products. For instance, according to data published by the United Nations Economic and Social Commission for Asia and the Pacific (ESCAP) in 2016, Asia Pacific constituted around 60% of the world’s geriatric population. It was estimated that in 2016, around 547 million people were aged above 60 years in Asia Pacific and this number is expected to double and reach around 1.3 billion by 2050.
For instance, in February 2017, Evolva Holding SA, a Switzerland-based pharmaceutical company launched Veri-te as its brand for resveratrol. Veri-te is readily used in a wide range of consumer health applications such as food supplements (tablets, capsules, and chews), cosmetics, energy, wellness drinks, and personal care products.
In December 2016, Helix Healthstore, a natural health supplement manufacturer expanded its product portfolio with the addition of Trans- Resveratrol-Super Youth Complex products in its range of premium health supplements. Trans- Resveratrol-Super Youth Complex is a potent antioxidant supplement and contains anti-aging properties that helps to prevent cell damages caused by free radicals, maintains longevity, and promote cellular rejuvenation.
Request for Customization of Research Report: https://www.coherentmarketinsights.com/insight/request-customization/2267
In August 2017, Jupiter Orphan Therapeutics, Inc. received U.S. Food and Drug Administration (FDA) Orphan Drug Designation for its trans-resveratrol formulation, JOTROL. Based on the phase II trial, utilizing resveratrol, conducted by the company and its partner Murdoch Children's Research Institute. JOTROL is expected to be used for the treatment of Friedreich's Ataxia.
Some side effects related with resveratrol is expected to hinder growth of the global resveratrol market during the forecast period. For instance, according to data published by National Institute of Health (NIH) in May 2018, resveratrol may cause side effects such as gastrointestinal upset, nausea, headache, and fatigue. It may also causes supplement-drug interactions with estrogens and anticoagulants, which is further expected to hinder its adoption.
Make an inquiry for purchasing this report @ https://www.coherentmarketinsights.com/insight/buy-now/2267
Key players operating in the global resveratrol market include SkinCeuticals, Evolva SA, DSM Nutritionals, Jeunesse Global, VitaMonk, Helix Healthstore, Terraternal, Andorra Life, ResVitale, LLC, Endurance Products Company, RevGenetics, SiChuan Xieli Pharmaceutical Co., Ltd., and others.
No comments:
Post a Comment